1. LBA44Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067). (23rd October 2018) Authors: Hodi, F S; Chiarion-Sileni, V; Gonzalez, R; Grob, J J; Rutkowski, P; Cowey, C L; Lao, C; Schadendorf, D; Wagstaff, J; Dummer, R; Ferrucci, P F; Smylie, M; Hill, A G; Hogg, D; Marquez-Rodas, I; Jiang, J; Rizzo, J; Larkin, J; Wolchok, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗